Q4 & FY 2022 Net Sales vs. 2021 Organic* Growth Q4:22 Reported Net Sales FY:22 Reported Net Sales vs Q4:21 vs FY:21 ($ in millions) Endoscopy $571 $2,221 7% 8% Urology $477 $1,773 12% 10% Neuromodulation $249 $917 5% 3% MedSurg $1,297 $4,911 8% 8% Interventional Cardiology Therapies $561 $2,228 5% 8% Watchman $280 $1,019 22% 24% Cardiac Rhythm Management $521 $2,100 6% 7% Electrophysiology $167 $585 25% 18% Cardiology $1,529 $5,932 10% 10% Peripheral Interventions $476 $1,899 9% 9% Cardiovascular $2,005 $7,831 9% 10% $3,302 $12,742 9% 9% † Other $(60) $(60) (100)% (+100)% Total Company $3,242 $12,682 7% 9% Guidance Range 7 to 9 percent ~9 percent Disclosed October 26, 2022 Q4 2022 organic* growth vs. 2021 excludes: FY 2022 organic* growth vs. FY 2021 excludes: ◦ Baylis Medical Company, Inc., acquired February 14, 2022 ◦ Preventice Solutions, Inc., acquired March 1, 2021 ◦ Specialty Pharmaceuticals business, divested March 1,2021 ◦ Farapulse, Inc. acquired August 6, 2021 ◦ The surgical business of Lumenis LTD., acquired September 1, 2021 ◦ Baylis Medical Company, Inc., acquired February 14, 2022 7 Q4 2022 Financial & Operational Highlights | February 1, 2023